Cargando…

Treatment discontinuation and tolerability as a function of dose and titration of duloxetine in the treatment of major depressive disorder

PURPOSE: We sought to better understand how dose and titration with duloxetine treatment may impact tolerability and treatment discontinuation in patients with major depressive disorder. PATIENTS AND METHODS: We investigated Phase III duloxetine trials. Group 1 was a single placebo-controlled study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Harada, Eiji, Shirakawa, Osamu, Satoi, Yoichi, Marangell, Lauren B, Escobar, Rodrigo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4714731/ https://www.ncbi.nlm.nih.gov/pubmed/26811681 http://dx.doi.org/10.2147/NDT.S86598

Ejemplares similares

Efficacy comparison of duloxetine and SSRIs at doses approved in Japan
por: Harada, Eiji, et al.
Publicado: (2015)

Multimodal functional and structural neuroimaging investigation of major depressive disorder following treatment with duloxetine
por: Fu, Cynthia HY, et al.
Publicado: (2015)

Duloxetine in the treatment of major depressive disorder
por: Goldstein, David J
Publicado: (2007)

Duloxetine in the treatment of major depressive disorder: an open-label study
por: Hudson, James I, et al.
Publicado: (2007)

Continuation treatment of major depressive disorder: is there a case for duloxetine?
por: Norman, Trevor R, et al.
Publicado: (2010)

Treatment patterns associated with Duloxetine and Venlafaxine use for Major Depressive Disorder
por: Ye, Wenyu, et al.
Publicado: (2011)

Residual symptoms in patients with partial versus complete remission of a major depressive disorder episode: patterns of painful physical symptoms in depression
por: Harada, Eiji, et al.
Publicado: (2016)

Duloxetine 60 mg once daily in the treatment of milder major depressive disorder
por: Perahia, DGS, et al.
Publicado: (2006)

An observational study of duloxetine versus SSRI monotherapy for the treatment of painful physical symptoms in Japanese patients with major depressive disorder: primary analysis
por: Kuga, Atsushi, et al.
Publicado: (2017)

The Effect of Initial Duloxetine Dosing Strategy on Nausea in Korean Patients with Major Depressive Disorder
por: Lee, Min-Soo, et al.
Publicado: (2012)

Duloxetine-Induced Hyponatremia in an Elderly Male Patient with Treatment-Refractory Major Depressive Disorder
por: Sun, Ching-Fang, et al.
Publicado: (2019)

An observational study of duloxetine versus SSRI monotherapy in Japanese patients with major depressive disorder: subgroup analyses of treatment effectiveness for pain, depressive symptoms, and quality of life
por: Kuga, Atsushi, et al.
Publicado: (2017)

Depression Treatment with Duloxetine and Reduction of Inability to Work
por: Happich, Michael, et al.
Publicado: (2012)

Baseline depressive symptoms as predictors of efficacy and tolerability of the treatment with duloxetine: a network analysis approach
por: Maciaszek, Julian, et al.
Publicado: (2023)

Duloxetine in the treatment of Major Depressive Disorder: A comparison of efficacy in patients with and without melancholic features
por: Mallinckrodt, Craig H, et al.
Publicado: (2005)

Escitalopram vs duloxetine in acute treatment of major depressive disorder: meta-analysis and systematic review
por: Maneeton, Benchalak, et al.
Publicado: (2018)

Associations among depression severity, painful physical symptoms, and social and occupational functioning impairment in patients with major depressive disorder: a 3-month, prospective, observational study
por: Harada, Eiji, et al.
Publicado: (2017)

The Effect of Food on the Single‐Dose Bioavailability and Tolerability of the Highest Marketed Strength of Duloxetine
por: Rizea‐Savu, Simona, et al.
Publicado: (2019)

Attributes of response in depressed patients switched to treatment with duloxetine
por: Sagman, D, et al.
Publicado: (2011)

Duloxetine-Induced Liver Injury in Patients with Major Depressive Disorder
por: Kang, Seung-Gul, et al.
Publicado: (2011)

Temporal Profiles and Dose-Responsiveness of Side Effects with Escitalopram and Duloxetine in Treatment-Naïve Depressed Adults
por: Polychroniou, Philip E., et al.
Publicado: (2018)

An open pilot study of zonisamide augmentation in major depressive patients not responding to a low dose trial with duloxetine: preliminary results on tolerability and clinical effects
por: Fornaro, Michele, et al.
Publicado: (2011)

Comparison of duloxetine and SSRI as a treatment option of painful physical symptoms associated with major depressive disorder
por: Haider, Miqdad, et al.
Publicado: (2017)

Changes in energy during treatment of depression: an analysis of duloxetine in double-blind placebo-controlled trials
por: Harada, E, et al.
Publicado: (2015)

Duloxetine in the treatment of stress urinary incontinence
por: Jost, Wolfgang H, et al.
Publicado: (2005)

The role of duloxetine in the treatment of anxiety disorders
por: De Berardis, Domenico, et al.
Publicado: (2008)

Duloxetine in the treatment of generalized anxiety disorder
por: Norman, Trevor R, et al.
Publicado: (2008)

Duloxetine in the treatment of generalized anxiety disorder
por: Wright, Alan, et al.
Publicado: (2009)

The safety and tolerability of duloxetine in depressed elderly patients with and without medical comorbidity
por: Wise, T N, et al.
Publicado: (2007)

Cholestatic Jaundice Induced by Duloxetine in a Patient with Major Depressive Disorder
por: Park, Young-Min, et al.
Publicado: (2010)

Duloxetine for the long-term treatment of Major Depressive Disorder in patients aged 65 and older: an open-label study
por: Wohlreich, Madelaine M, et al.
Publicado: (2004)

Coding of adverse events of suicidality in clinical study reports of duloxetine for the treatment of major depressive disorder: descriptive study
por: Maund, Emma, et al.
Publicado: (2014)

Dose/exposure–response modeling in dose titration trials: Overcoming the titration paradox
por: Kristensen, Niels Rode, et al.
Publicado: (2022)

A Systematic Review of Efficacy, Safety, and Tolerability of Duloxetine
por: Rodrigues-Amorim, Daniela, et al.
Publicado: (2020)

Duloxetine in Psychiatric Disorders: Expansions Beyond Major Depression and Generalized Anxiety Disorder
por: Muscatello, Maria Rosaria Anna, et al.
Publicado: (2019)

Analysis of HAM-D scores and working ability in an observational study of Japanese patients with major depressive disorder and painful physical symptoms treated with duloxetine or SSRI monotherapy
por: Kuga, Atsushi, et al.
Publicado: (2019)

A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD
por: Mahableshwarkar, Atul R., et al.
Publicado: (2015)

Safety and tolerability of duloxetine in the treatment of patients with fibromyalgia: pooled analysis of data from five clinical trials
por: Choy, Ernest H. S., et al.
Publicado: (2009)

Efficacy and tolerability of short-term duloxetine treatment in adults with generalized anxiety disorder: A meta-analysis
por: Li, Xinyuan, et al.
Publicado: (2018)

Special considerations in the treatment of patients with bipolar disorder and medical co-morbidities
por: McLaren, Kimberly D, et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_s4fsdlrqdosqu162fu8rhdc4kh